Table 1 Clinical and laboratory characteristics at the time of initial diagnosis of chronic myelomonocytic leukemia in 138 Mayo Clinic patients who subsequently underwent allogeneic stem cell transplantation stratified by pre-transplant history of blast transformation.

From: Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

Variables

Entire cohort (n = 138)

Patients transplanted in chronic phase CMML (n = 104)

Patients with pre-transplant history of blast transformation (n = 34)

P value

 

Age at diagnosis, years, median (range)

62 (18–75)

62 (28–75)

58 (18–73)

0.05

 

Male, n (%)

85 (62)

63 (60)

22 (65)

0.6

 

Age at ASCT, years, median (range)

63 (18–76)

64 (29–76)

59.5 (18–75)

0.2

 

WHO subtype, n (%) (evaluable = 130)

0.1

 

CMML1

102 (78)

80 (82)

22 (69)

  

CMML2

28 (22)

18 (18)

10 (31)

  

FAB subtype, n (%) (evaluable = 129)

0.1

 

Dysplastic

70 (54)

56 (58)

14 (44)

  

Proliferative

59 (46)

41 (42)

18 (56)

  

Leukocytes, ×109/L; median (range)

10 (1.4–128)

10.3 (1.4–128)

21.6 (2.4–112)

0.1

 

AMC, ×109/L; median (range)

2.3 (0.08–46)

2.1 (0.08–46)

3.5 (0.1–36)

0.1

 

Hemoglobin, g/dl; median (range)

10.65 (4–15.9)

10.8 (4–15.9)

10.3 (4.5–14.9)

0.3

 

Platelets, ×109/L; median (range)

101 (13–767)

100 (13–767)

116 (13–325)

0.5

 

Circulating blast %; median (range)

0 (0–15)

0 (0–15)

1 (0–12)

0.1

 

Bone marrow blast %; median (range)

3 (0–18)

3 (0–18)

5 (0–17)

0.9

 

CPSS-Mol score, n (%) (evaluable = 82)

0.2

 

Low

14 (17)

12 (17)

2 (17)

  

Intermediate-1

9 (11)

9 (13)

0

  

Intermediate-2

33 (40)

26 (37)

7 (58)

  

High

26 (32)

23 (33)

3 (25)

  

BLAST score, n (%) (evaluable = 129)

0.2

 

Low

49 (38)

41 (42)

8 (26)

  

Intermediate

57 (44)

40 (41)

17 (55)

  

High

23 (18)

17 (17)

6 (19)

  

BLAST-mol score, n (%) (evaluable = 79)

0.8

 

Low

17 (21)

15 (22)

2 (17)

  

Intermediate

34 (43)

29 (43)

5 (41)

  

High

28 (36)

23 (34)

5 (42)

  

Cytogenetics, n (%)

0.5

 

Normal/loss of Y chromosome

93 (69)

73 (71)

20 (65)

  

Abnormal

41 (31)

30 (29)

11 (35)

  

Mutations, n (%) (evaluable = 86)

 

ASXL1

49 (56)

43 (59)

6 (42)

0.2

 

TET2

38 (44)

33 (46)

5 (35)

0.4

 

SRSF2

35 (40)

29 (40)

6 (42)

0.9

 

RUNX1

17 (24)

17 (24)

0

0.01

 

DNMT3A

8 (10)

8 (12)

0

0.09

 

SETBP1

7 (8)

6 (9)

1 (7)

0.9

 

PHF6

8 (10)

7 (10)

1 (7)

0.8

 

First line chemotherapy prior to ASCT, n (%) (evaluable = 125)

0.01

 

HMA/Venetoclax

75 (60)

64 (68)

11 (35)

  

Intensive chemotherapy

29 (23)

10 (11)

19 (61)

  

Othera/clinical trials

16 (13)

15 (16)

1 (4)

  

None

5 (4)

5 (5)

   

HMA therapy prior to ASCT, n (%) (evaluable = 137)

0.01

 

Yes

78 (57)

66 (64)

12 (36)

  

No

59 (43)

37 (36)

22 (64)

  

Intensive chemotherapy prior to ASCT, n (%) (evaluable = 137)

 

0.01

 

Yes

40 (29)

13 (13)

27 (79)

  

No

97 (71)

90 (87)

7 (21)

  
  1. AMC absolute monocyte counts, ASCT allogeneic stem cell transplant, FAB French-American-British classification system, HMA hypomethylating agent, WHO World Health Organization.
  2. aHydroxyurea, erythropoietin agonist, danazol, Ruxolitinib are included in ‘other” if no chemotherapy received.
  3. Bold values indicate statistically significant P value.
Back to article page